Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare

May 11, 2016

|

NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences.

According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer high sensitivity and specificity, as well as a fast and affordable method for targeted NGS oncology testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

By a Third

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

Faster, Faster

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Push for Sequencing

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

PNAS Papers Take on Polar Bear Evolution, Siberian Hamster Seasonality, and More

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.

Featured White Papers

BlueBee Data Security & Compliance

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jun

25

Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

24

Featured Webinar

Comparison of Group B Streptococcus Molecular Assays for Routine Screening in Pregnant Women

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul

25

Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Menu